Anti-EMSY polyclonal antibody in lung cancer research

March 2022 (Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, USA)

Lung cancer: deregulation of the ubiquitin-proteasome system promotes suppression of innate immunity, which fosters lung cancer immune evasion.

In a new study, Marzio et al. (Cell, 2022) show that KEAP1 targets the transcriptional repressor EMSY for ubiquitin-mediated degradation to regulate homologous recombination repair and anti-tumor immunity in lung cancer.

The anti-EMSY HPA050777 (BRCA2 interacting transcriptional repressor) polyclonal antibody from Atlas Antibodies was used in the study.

Read whole article here: